Acasti Pharma Inc
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
GRCE$1.86-0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Three months ended | ||
|---|---|---|
| June 30,2024 | June 30,2023 | |
| (Expressed in thousands) | $ | $ |
| Cash flows used in operating activities: | ||
| Net loss | (2,617) | (4,023) |
| Adjustments: | ||
| Depreciation expense | 1 | 7 |
| Stock-based compensation | 238 | 78 |
| Change in fair value of derivative warrant liabilities | (1,395) | — |
| Deferred income tax benefit | (724) | (289) |
| Loss on disposal of equipment | — | 13 |
| Changes in operating assets and liabilities: | ||
| Receivables | 326 | (35) |
| Prepaid expenses | (339) | (529) |
| Trade and other payables | 913 | (1,449) |
| Operating lease right of use asset | — | (13) |
| Net cash used in operating activities | (3,596) | (6,240) |
| Cash flows from investing activities: | ||
| Purchase of short-term investments | (15) | — |
| Net cash used in investing activities | (15) | — |
| Effect of exchange rate fluctuations on cash and cash equivalents | — | (2) |
| Net decrease in cash and cash equivalents | (3,611) | (6,242) |
| Cash and cash equivalents, beginning of period | 23,005 | 27,875 |
| Cash and cash equivalents, end of period | 19,394 | 21,633 |
| Cash and cash equivalents are comprised of: | ||
| Cash | 3,041 | 5,413 |
| Cash equivalents | 16,353 | 16,220 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.